Search

A recent study conducted at the University Medical Center Utrecht in the Netherlands examined the outcomes of patients who underwent left ventricular assist device (LVAD) exchange. The study found that while the mortality rate for LVAD exchange was relatively low, other post-operative complications were common. Patients who had the HeartWare Ventricular Assist Device (HVAD) as their initial device were at a higher risk of developing right heart failure and respiratory failure after the exchange. The study highlights the need for further research and improved strategies to minimize complications associated with LVAD exchange. [Extracted from the article]

A recent report from the University of Rostock in Germany discusses the use of computational fluid dynamics (CFD) simulations to study ventricular assist devices (VADs) and their interaction with the cardiovascular system. The researchers aimed to validate critical simulation parameters for accurate VAD simulations and found that mesh size and time step sizes had the greatest influence on the calculated pump performance. The study contributes to advancing VAD simulations, which can ultimately enhance clinical efficacy and patient outcomes. For more information, the full article can be accessed through the provided link. [Extracted from the article]

A recent study conducted by the University of Maryland School of Medicine highlights the risks associated with left ventricular assist devices (LVADs) used in patients with end-stage heart disease. While advancements in LVAD technologies have improved patient outcomes, there are still significant risks involved. The study focuses on a laparoscopic technique for driveline tunneling during LVAD implantation, which can reduce the risk of intraabdominal injury. The researchers emphasize the importance of careful management during the procedure to prevent complications. This research provides valuable insights for healthcare professionals and patients considering LVAD implantation. [Extracted from the article]

A patent application has been submitted for a "Delivery Tube With Braid" to the US Patent and Trademark Office. This invention is a left-ventricular assist device that includes an impeller and a delivery tube. The delivery tube is designed to pass through different parts of the aorta, with an outer layer that varies in flexural rigidity along its length. The device also includes a drive cable that rotates the impeller to pump blood from the left ventricle into the aorta. The patent application provides detailed information about the design and composition of the delivery tube. [Extracted from the article]

A patent application has been submitted for a ventricular assist device with an impeller-stabilizing spring. The device is designed to assist and unload cardiac chambers in patients with a failing heart or those at risk during coronary interventions. The motion-cushioning spring acts as a shock absorber, providing cushioning to the axial back-and-forth motion of the impeller. The device also includes a distal thrust bearing to prevent axial motion of the impeller in response to pressure variations. An elastomeric material can be coupled to the motion-cushioning spring to reduce the risk of thrombi and hemolysis. The patent application provides further details and claims for the apparatus. [Extracted from the article]

A recent report discusses research on early ventricular arrhythmias (EVAs) after left ventricular assist device (LVAD) implantation. The study found that EVAs are a common complication after LVAD implantation and are associated with an increased risk of 30-day mortality. Risk factors for EVAs include a history of end-stage renal disease, preoperative electrical storm, and previous implantable cardiac defibrillator therapy. The study suggests that further research is needed to better understand the incidence and prognostic implications of EVAs in patients with LVAD. [Extracted from the article]

A recent study conducted by the Medical University of Silesia examined the impact of long-term continuous-flow left ventricular assist device (LVAD) therapy on fibrin clot permeability in patients with end-stage heart failure. The researchers found that patients on LVAD therapy experienced a decrease in fibrin clot permeability over time. This decrease was associated with higher fibrinogen concentration and factor VIII activity. Additionally, patients without adverse events showed a trend towards normalization of fibrin clot permeability, suggesting a potential link between clot structure and thromboembolic and bleeding complications. [Extracted from the article]

A recent study conducted by researchers at Soochow University in Suzhou, China, has proposed a new adaptive proportional derivative (APD) control system for left ventricular assist devices (LVADs). The APD control system aims to address the issue of high power consumption caused by the unclear mechanism of liquid disturbance during the lifting-up of the magnetic bearing in LVADs. The researchers developed a mathematical model to describe the rotor's operation in liquid filling and analyzed the disturbance caused by the liquid. The experimental results showed that the APD control system improved dynamic performance, reduced power consumption, and resulted in a shorter rise time without overshoot of rotor displacement compared to traditional fixed configurations. [Extracted from the article]

A new report from the University of Pennsylvania discusses the challenges of managing aortic valve damage after the implantation of a left ventricular assist device (LVAD). The study reviewed the experiences of six patients who required intervention for aortic regurgitation after LVAD implantation. The interventions included open surgical procedures and percutaneous strategies, such as device placement and transcatheter aortic valve replacement. The results showed resolution of aortic regurgitation and improved hemodynamics in all patients, although there were some deaths. The researchers concluded that with a tailored risk-adjusted approach, acceptable results can be achieved in managing LVAD-induced aortic valve regurgitation. [Extracted from the article]

A recent study conducted at San Diego State University has found that the formation of a vortex in the aortic sinus is crucial for optimizing blood flow in patients with left ventricular assist devices (LVADs). The researchers used a mock circulatory loop combined with an LVAD to visualize vortex formation in an experimental model of the aortic root. They discovered that maintaining intermittent aortic valve opening is important for LVAD patients, as disruption of the vortex can lead to flow stagnation and thrombus formation. This study provides valuable insights into the dynamics of blood flow during LVAD support and highlights the need for further investigation in this area. [Extracted from the article]

A patent application for a ventricular assist device has been filed by inventors from Israel. The device is designed to assist and unload cardiac chambers in patients with a failing heart or those at risk during coronary interventions. The device includes an axial shaft, an impeller, a frame, a pump-outlet tube, and an inlet guard with holes for blood flow. The device also features a thrust bearing to prevent axial motion of the shaft. The patent application provides detailed descriptions and specifications for the device. [Extracted from the article]

A patent application has been submitted for a new bearing housing design for a ventricular assist device, which is a mechanical circulatory support device used to assist the functioning of a failing heart. The inventors have developed an apparatus that includes an axial shaft, an impeller, a frame, a pump-outlet tube, and an inlet guard. The bearing housing, which stabilizes the axial shaft, is located within the frame, with at least 50% of its length disposed within the frame. The invention aims to improve the efficiency and stability of ventricular assist devices. [Extracted from the article]

A patent application has been submitted for a ventricular assist device with an optical fiber. The device is designed to assist and unload cardiac chambers in patients with a failing heart or those at risk during coronary interventions. The device includes a motion-cushioning spring that acts as a shock absorber and is coupled to an elastomeric material to reduce the risk of thrombi and hemolysis. The device also features a distal thrust bearing to prevent axial motion of the impeller and a pump-outlet tube that can be used to measure blood pressure. [Extracted from the article]

A patent application for an "Inlet Guard For Blood Pumps" has been filed by inventors from Israel. The ventricular assist device described in the application is designed to assist and unload cardiac chambers in patients with failing hearts or those at risk during coronary interventions. The device includes an axial shaft, an impeller, a frame, a pump-outlet tube, and an inlet guard with holes that allow blood to flow to the impeller. The patent application provides detailed information about the design and components of the device. [Extracted from the article]

A patent application has been submitted for a device called the "Curved Tip For Blood Pump" that is designed to assist and unload cardiac chambers by being inserted into the left ventricle of the heart. The device includes a delivery tube with an elongation-resistant fiber, a pump-outlet tube, and a blood pump. The patent application provides detailed information on the design and configuration of the device, which aims to improve the efficiency and effectiveness of left-ventricular assist devices (LVADs). [Extracted from the article]

A patent application titled "Packaging For A Ventricular Assist Device" has been published online. The inventors of the device are Friedland, Ori; Lubinsky, Gad; Rosenblum, Daniel; Rozenfeld, Avi; Troshin, Victor; Tuval, Yosi; Zemer Harel, Hagit. The ventricular assist device is a mechanical circulatory support device used to assist and unload cardiac chambers in patients with a failing heart or at risk during percutaneous coronary interventions. The device includes a motion-cushioning spring that acts as a shock absorber and is coupled to an elastomeric material to reduce the risk of thrombi and hemolysis. The patent application also describes the use of a distal thrust bearing and a proximal motion-cushioning spring to stabilize the impeller of the device. The apparatus is designed to be packaged in a non-radially constrained configuration for delivery to the left ventricle using a delivery catheter. The packaging includes a slanted surface to reduce the likelihood of air bubbles entering the catheter. [Extracted from the article]

Inventors from Israel have filed a patent application for a ventricular assist device that aims to assist and unload cardiac chambers in patients with failing hearts or those at risk during coronary interventions. The device includes a motion-cushioning spring and an elastomeric material to reduce the risk of thrombi and hemolysis. It also features a distal thrust bearing to prevent axial motion of the impeller in response to pressure variations. The device includes an axial shaft, an impeller, a frame, and a distal thrust bearing, as well as a motion-cushioning spring, an elastomeric material, a purging system, and a pump-outlet tube for blood flow. [Extracted from the article]

A study conducted by the University of Birmingham in the United Kingdom examined the clinical and cost-effectiveness of left ventricular assist devices (LVADs) as destination therapy for patients with advanced heart failure who are ineligible for heart transplantation. The study found that LVAD therapy improves patient survival and reduces complications compared to medical management. However, the cost-effectiveness of LVADs compared to medical management may not be favorable according to cost-effectiveness criteria applied in the UK. The study suggests that further research and an audit of the costs of medical management are needed to decrease uncertainty in the economic evaluation. [Extracted from the article]

A patent application has been submitted for a new invention called "Distally-Facing Blood-Outlet Openings." The invention is a left-ventricular assist device that helps support the heart by pumping blood from the left ventricle into the aorta. The device includes a pump-outlet tube with blood-outlet openings, an impeller to pump the blood, a delivery tube, and an expandable element. The expandable element surrounds the delivery tube and helps center it within the aorta. The patent application provides detailed descriptions and claims for the invention. [Extracted from the article]

A study conducted at La Paz University Hospital in Madrid, Spain, examined the combined use of transcatheter edge-to-edge therapy (TEER) and mechanical circulatory support devices (MCS) in patients with cardiogenic shock (CS) and mitral regurgitation (MI). The study found that TEER in combination with MCS showed promising results, with a high device procedural success rate and acceptable mortality and heart failure readmission rates at the 12-month follow-up. The research suggests that this approach could be a therapeutic alternative for patients with CS and MR who require MCS. [Extracted from the article]

This article discusses a patent application for a medical device related to the field of cardiology and angiology. The device is specifically designed for the aorta and left ventricular assist. The patent application provides detailed descriptions and claims for the apparatus and its assembly. The article provides factual information about the patent application and does not offer any judgments or opinions. [Extracted from the article]

A recent report from the Medical College of Wisconsin discusses a case involving a patient with a HeartMate 3 left ventricular assist device (LVAD). The patient experienced a disconnection of the device's bend relief, which caused a laceration of the outflow graft. This resulted in a left chest hematoma and exsanguinating hemorrhage. The patient underwent emergency surgery to repair the graft and remove the disconnected bend relief. This is the first reported case of this specific malfunction in the HeartMate 3 LVAD. [Extracted from the article]

This article discusses a patent application for a new medical device called a "Pump-Outlet Tube." The device is designed to assist and unload cardiac chambers in patients with a failing heart or those at risk during coronary interventions. It includes a pump-outlet tube with blood-outlet openings that is inserted into the aorta and left ventricle of the heart. The device has an impeller to pump blood and an expandable element to center it within the aorta. The patent application provides further details and claims for the device. [Extracted from the article]

Researchers at Mayo Clinic have reported on a case involving a 45-year-old female with advanced heart failure and ventricular arrhythmias. The patient received treatment including antiarrhythmic medications, inotrope support, diuretics, and the placement of an Impella 5.5 device for mechanical circulatory support. Due to persistent ventricular tachycardia, a bilateral stellate ganglion blockade was performed along with intensified antiarrhythmic therapy and deep sedation. The case highlights the potential benefits of combining mechanical circulatory support with stellate ganglion blockade in managing malignant ventricular arrhythmias. [Extracted from the article]

Researchers at the University of North Carolina have published a consensus statement on strategies to prevent and manage hemocompatibility-related adverse events (HRAEs) in patients with a durable, continuous-flow left ventricular assist device (CF-LVAD). Despite improvements in care, HRAEs remain a concern and can lead to significant morbidity and mortality. The statement provides evidence-based recommendations for the optimal management of oral anticoagulant and antiplatelet medications, parenteral anticoagulant medications, high-risk patients, and those experiencing thrombotic or bleeding events. It aims to assist clinicians in providing the best possible care for CF-LVAD patients. The research has been peer-reviewed and published in The Journal of Heart and Lung Transplantation. [Extracted from the article]

A patent application has been submitted for a ventricular assist device that aims to help patients with a failing heart or those at risk during coronary interventions. The device includes a motion-cushioning spring that acts as a shock absorber for the impeller's back-and-forth motion. It also features a distal thrust bearing to prevent axial motion of the impeller in response to pressure changes. The patent application provides detailed descriptions and claims for different configurations and features of the device, including an elastomeric material covering part of the axial shaft, a purging system, and a pump-outlet tube. [Extracted from the article]

Researchers at Queen's Medical Center conducted a study to assess the role of cardiac magnetic resonance-derived right ventricular ejection fraction (CMR-RVEF) in predicting the risk of right heart failure (RHF) in patients who underwent left ventricular assist device (LVAD) implantation. The study included 42 patients who underwent CMR before LVAD implantation, and the results showed that CMR-RVEF may not predict post-LVAD RHF. The researchers concluded that large multicenter studies are needed to confirm these findings. This information is available in an article published in JHLT Open. [Extracted from the article]

A recent study conducted by researchers at the University of Louisville examined the impact of heart transplants from donors after circulatory death (DCD) on patients with a durable left ventricular assist device (LVAD). The study found that there was no significant difference in postoperative outcomes or overall survival between recipients of DCD and donors after brain death (DBD). However, recipients with durable LVADs from DCD donors had a higher rate of treatment for rejection within the first year. These findings suggest that the use of DCD donors may help decrease waitlist time for patients with durable LVADs. [Extracted from the article]

A study conducted by Technical University Valencia (TU Valencia) has provided new insights into the performance of left ventricular assist devices (LVADs) using computational fluid dynamics (CFD) simulations. The study analyzed the transient behavior of two centrifugal LVADs, the HeartWare VAD and HeartMate3, using a scale-resolving methodology. The LVAD models were coupled with a 2-element Windkessel model to account for vascular resistance and compliance. The study found that the quasi-steady approach, which provides a preliminary approximation of pulsatile flow, can be a useful tool for deciding the characteristics of the pulsatile speed law before running a transient CFD simulation. [Extracted from the article]

A recent study conducted at MedStar Washington Hospital Center examined the impact of cardiac resynchronization therapy (CRT) on patients who received a durable left ventricular assist device (LVAD) implantation. The researchers found that there is no consensus on postoperative management for patients with preoperative CRT. The study revealed that patients with preoperative CRT who had it turned "on" after LVAD implantation had a significantly increased risk of mortality compared to those with preoperative CRT turned "off." However, there was no significant difference in the incidence of ventricular arrhythmias between patients with and without postoperative CRT. The researchers concluded that further clinical trials are needed to determine the best CRT programming strategy following LVAD implantation. [Extracted from the article]

A new study conducted at Karolinska University Hospital in Stockholm, Sweden, examined the outcomes of left ventricular assist device (LVAD) implantations. The study analyzed data from 44 patients who received the HeartMate 3 (HM3) LVAD between 2017 and 2022. The study found that the median intensive care unit stay after implantation was 8 days, and the median hospital stay was 28 days. The 1-year survival rate with LVAD was 85%, and the 2-year survival rate was 80%. The study's results align with those of other studies and international registries. [Extracted from the article]

A recent study conducted by researchers at Washington University provides new insights into the use of ventricular assist devices (VADs) for failed stage II palliation (S2P). The study analyzed data from 34 patients implanted with systemic VADs after S2P, finding that adverse events such as infection, strokes, bleeding, dialysis, and respiratory failure were common. However, the study also showed encouraging clinical outcomes, with 76% of patients surviving to transplant or recovery and 56% surviving to 1 year post-explant. The researchers emphasize the need for ongoing collaboration to determine optimal strategies for SVAD support. [Extracted from the article]

A new study conducted by a researcher at the University of Siena explores the use of left ventricular assist devices (LVADs) as a therapeutic strategy for advanced heart failure. The study highlights the importance of precise evaluation and management of patients with long-term LVADs, as they are associated with complications such as infections and device mis-positioning. The research emphasizes the use of multimodality imaging techniques to assess LVAD candidates and guide the implantation process. The study provides valuable insights into the evaluation and management of patients with advanced heart failure undergoing LVAD implantation. [Extracted from the article]

A study conducted by the University of Missouri has found that caregivers of older patients with advanced heart failure may experience burden in providing care. The study included older patients receiving advanced surgical heart failure therapies and their caregivers at 13 sites in the United States. The researchers used the Kansas City Cardiomyopathy Questionnaire to assess patient health status and the Oberst Caregiving Burden Scale to assess caregiver burden. The study found that changes in patient health status were associated with caregiver burden, highlighting the potential for assessments to identify caregivers at risk of increased burden. [Extracted from the article]

A recent study conducted by researchers from Stony Brook University Hospital explores the impact of diabetes mellitus (DM) on outcomes in patients with left ventricular assist devices (LVADs). The study highlights the challenges posed by comorbidities such as hypertension, dyslipidemia, peripheral vascular disease, and renal dysfunction in managing LVADs in patients with DM. The research also discusses the bidirectional relationship between DM and LVADs, with some studies showing decreased hemoglobin A1c levels post-LVAD implantation. However, there is no consensus in the literature regarding mortality or major adverse outcomes in DM patients after LVAD implantation. [Extracted from the article]

A clinical trial, NCT06510322, is being conducted to determine if sildenafil can reduce vascular aging in patients receiving left ventricular assist device (LVAD) support. LVAD therapy improves survival in advanced heart failure patients, but vascular aging can lead to serious complications. The trial will measure various indicators to assess the effects of sildenafil on vascular remodeling and related adverse events. The study will involve 50 participants and will be led by Dr. Omar Saeed at Montefiore Medical Center in the United States. Contact information is provided for those interested in participating. [Extracted from the article]

A new study conducted by researchers at the University of Milano Bicocca in Italy explores the treatment paths and resources used for patients with a left ventricular assist device (LVAD). The study found that the number of people with end-stage heart failure implanted with an LVAD is increasing, leading to a need for hospitals to develop new treatment paths. The survey administered to 22 Italian hospitals revealed that nurses play a crucial role in the care of LVAD patients, often serving as LVAD coordinators and involved in activities such as health education and monitoring. However, the study also highlighted the need for better integration of palliative care and specific education for the multi-professional team. [Extracted from the article]

A new report from the Polytechnic University of Madrid discusses the impact of different electrode placement patterns on the electromagnetic interference generated by Left Ventricular Assist Devices (LVADs) during electrocardiogram (ECG) performance. LVADs are mechanical circulatory assist devices used to enhance survival and quality of life in patients with advanced heart failure. The study found that individualizing the electrode placement scheme is crucial for minimizing noise generated by LVADs, and adjusting the low-pass filter to 40 Hz could generally reduce artifact generation, although it may have clinical limitations. The research highlights the importance of managing electromagnetic interference in ECGs for patients with LVADs. [Extracted from the article]

A recent report from Copenhagen University Hospital discusses the prevalence and impact of iron deficiency in patients with left ventricular assist devices (LVADs). The review found that iron deficiency is common in LVAD patients, with prevalence ranging from 40% to 82%. IV iron repletion was found to effectively resolve iron deficiency in most patients without adverse events. However, the effects of iron deficiency and repletion on post-implant survival and exercise capacity are still unknown. The report suggests that further research is needed to clarify the significance of iron deficiency in LVAD patients. [Extracted from the article]

A recent study conducted at the National Cerebral and Cardiovascular Center in Suita, Japan, examined the effects of fenestration on the hemodynamics of ventricular assist device (VAD) support in patients with failing Fontan circulation. Fenestration is a surgical procedure that creates a small communication between the extracardiac conduit and the atrium during the Fontan operation. The study found that fenestration did not impair the hemodynamics under VAD support and may not require closure. The effects of fenestration were more significant in patients with higher pulmonary vascular resistance index. [Extracted from the article]

Researchers at the TEDA International Cardiovascular Hospital have conducted a study to understand the phenomenon of gas production in left ventricular assist devices (LVADs). The study found that gas production is associated with higher blood oxygen levels, higher rotation speeds, and intrapump thrombosis. The gas released is likely to be oxygen, and the degassing phenomenon serves as a warning sign for pump thrombosis. This research provides valuable insights into the mechanisms of gas production in LVADs. [Extracted from the article]

A recent study conducted by researchers from Pennsylvania State University (Penn State) College of Medicine and Milton S. Hershey Medical Center compared two methods of placing a temporary right ventricular assist device (t-RVAD) in patients with right ventricular failure (RVF) after left ventricular assist device (LVAD) placement. The study found that there was no significant difference in the length of ICU stay, hospital length of stay, discharge rates, or one-year survival between the two methods. However, the percutaneous t-RVAD group had less time on the ventilator and required fewer blood products. The researchers concluded that percutaneous t-RVAD support is a viable option for patients who undergo LVAD placement and require right ventricular mechanical support. [Extracted from the article]

A recent study conducted at the University of Cologne in Germany has provided new data on left ventricular assist devices (LVADs). The study focused on the evaluation of intraoperative right ventricular myocardial work indices during LVAD implantation. The researchers found that combining right ventricular myocardial strain with loading conditions can provide insights into cardiac mechanics, energetics, and efficiency. This technique has not been previously described intraoperatively using transesophageal echocardiography. The study suggests that monitoring right ventricular myocardial work indices during LVAD implantation may assist in making decisions during the procedure. [Extracted from the article]

Researchers at the University Hospital in Lausanne, Switzerland conducted a study on the clinical outcomes of patients with advanced heart failure who were supported by the HeartMate 3 left ventricular assist device (LVAD). The study compared patients who received the LVAD as a bridge to transplantation (BTT) versus those who received it as destination therapy (DT). The findings showed that patients in the DT group had poorer outcomes, including lower survival rates and more adverse events. The researchers concluded that better patient selection is needed for LVAD-DT in order to improve outcomes and reduce adverse events. [Extracted from the article]

A patent has been issued for a tubular pulsatile ventricular assist device (PVAD) system developed by inventors from Arizona State University. The system aims to provide forward flow of blood in a pulsatile, peristaltic, and non-hemolytic manner, reducing the amount of blood clotting associated with current ventricular assist devices on the market. The system consists of a tubular housing with a membrane divided into panels, ports, and inflatable wedges that create a peristaltic movement along the length of the membrane. The invention offers potential clinical advantages such as maintaining red blood cell integrity, reducing turbulent blood flow, and accommodating blood vessel stretching. [Extracted from the article]

A recent study conducted by researchers at the University of Pittsburgh examined the feasibility of using robotic assistance in the suturing of outflow graft anastomosis during minimally invasive left-ventricular assist device implantation. The study involved eight cadaver studies and found that the procedure was feasible in all attempts, with acceptable anastomotic times and good suture alignment. Surgeons reported high levels of comfort and confidence in completing the anastomoses. This research provides valuable insights into the potential use of robotic technology in cardiac surgery. [Extracted from the article]

A study conducted by researchers at Tel Aviv University analyzed online forums to identify the knowledge gaps and informational needs of individuals with left ventricular assist devices (LVADs). The study examined forum posts and comments from the MyLVAD.com website from 2015 to 2023. The analysis revealed six main categories of informational needs, including clothing, complications/adverse effects, LVAD pros and cons, self-care, therapy, and recent LVAD implantation. The findings highlight the importance of tailored educational resources to address these needs and improve LVAD patient care. [Extracted from the article]